Zinacef® 250 mg powder for solution or suspension for injection
- Name:
Zinacef® 250 mg powder for solution or suspension for injection
- Company:
GlaxoSmithKline (Ireland) Ltd
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 01/02/19
(Click to Download)Click on this link to Download PDF directly
GlaxoSmithKline (Ireland) Ltd
 Ltd.jpg)
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 1 February 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 6 - date of revision
Updated on 1 February 2019 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.4 'Special warnings and precautions for use' - addition of intracameral use and ocular toxicity data and addition of sodium excipient warning statements.
Updated on 16 July 2015 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 16 July 2015 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 15 July 2015 PIL
Reasons for updating
- New PIL for new product
Updated on 15 July 2015 PIL
Reasons for updating
- Change to date of revision
- Change to MA holder contact details
Updated on 21 April 2015 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.2 – Clarification of method for intramuscular administration
Section 4.8 – Updated HPRA reporting details
Section 5.1 – Updated microbiological susceptibility tables
Updated on 20 April 2015 PIL
Reasons for updating
- Change to dosage and administration
- Change to, or new use for medicine
- Change to warnings or special precautions for use
- Change to date of revision
Updated on 21 July 2014 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4 - Clinical particulars
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
- Change to section 5 - Pharmacological properties
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 2 to 5.3 and section 6.5 – all text changed in line with the harmonised annexes
Updated on 18 July 2014 PIL
Reasons for updating
- Change to, or new use for medicine
- Change to warnings or special precautions for use
- Change to instructions about missed dose
- Change to instructions about overdose
- Change to storage instructions
- Change to side-effects
- Change to drug interactions
- Change to information about drinking alcohol
- Change to information about pregnancy or lactation
- Change to information about driving or using machinery
- Change to how the medicine works
- Change to further information section
- Change to date of revision
- Change of special precautions for disposal
- Change due to harmonisation of PIL
Updated on 17 November 2011 PIL
Reasons for updating
- Change due to user-testing of patient information
Updated on 18 March 2010 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.2 - Posology and method of administration
- Change to section 6.2 - Incompatibilities
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.6 - Special precautions for disposal and other handling
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains 250mg of cefuroxime as cefuroxime sodium.
For a full list of excipients, see section 6.1
3. PHARMACEUTICAL FORM
Powder for solution or suspension for injection
Powder for suspension for intramuscular injection
A white to cream powder
4.2 Posology and Method of Administration
Zinacef is administered by intravenous or intramuscular injection.
Zinacef injection is for intravenous and/or intramuscular administration.
Zinacef is a white to cream powder to which appropriate amounts of water are added to prepare an off-white suspension for intramuscular use or a yellowish solution for intravenous administration.
Adults: The total daily dosage is in the range of 1500 to 6000mg in divided doses, the usual dose is 750 mg thrice daily.
…..etc.
6.2 Incompatibilities
Zinacef should not be mixed in the syringe with aminoglycoside antibiotics.
The pH of 2.74% w/v Sodium Bicarbonate Injection BP considerably affects the colour of the solution and therefore this solution is not recommended for the dilution of Zinacef.
However, if required, for patients receiving Sodium Bicarbonate Injection by infusion the Zinacef may be introduced into the tube of the giving set.
6.3 Shelf Life
Powder
2 Years 24 months.
Reconstituted Solution
Chemical and physical in-use stability has been demonstrated for 5 hours at 25°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution/dilution (etc) has taken place in controlled and validated aseptic conditions.
Single use only. Discard any remaining contents after use.
6.4 Special Precautions for Storage
Do not store above 25°C. Keep vial in the outer carton to protect from light.
For storage conditions following reconstitution, please refer to section 6.3.
6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product. Instructions for Use and Handling
Intramuscular:
Add 1 ml Water for Injections to 250 mg Zinacef. Shake gently to produce an off white opaque suspension.
Intravenous:
Dissolve Zinacef in Water for Injections using at least 2 ml for 250 mg cefuroxime to produce a yellowish solution.
Updated on 17 September 2007 SmPC
Reasons for updating
- Correction of spelling/typing errors
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 10 August 2007 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Use of cefuroxime should be reserved for moderately serious or severe infections.
Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactams.
Cephalosporin antibiotics at high dosage should be given with caution to patients receiving concurrent treatment with potent diuretics such as frusemide or aminoglycosides, as renal impairment has been reported with these combinations. Renal function should be monitored in these patients, the elderly, and those with pre-existing renal impairment (see 4.2 Posology and Method of Administration).
As with other antibiotics, prolonged use of cefuroxime may result in the overgrowth of Candida. Prolonged use may also result in the overgrowth of non-susceptible organisms (e.g. Candida, Enterococci, and Clostridium difficile), which may require interruption of treatment.
Infections and infestations
Rare: Candida overgrowth from prolonged use.
Updated on 30 August 2006 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.4. Special Warnings and Precautions for Use
Use of cefuroxime should be reserved for moderately serious or severe infections.
Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactams.
Cephalosporin antibiotics at high dosage should be given with caution to patients receiving concurrent treatment with potent diuretics such as frusemide or aminoglycosides, as renal impairment has been reported with these combinations. Renal function should be monitored in these patients, the elderly, and those with pre-existing renal impairment (see 4.2 Posology and Method of Administration).
As with other antibiotics, prolonged use of cefuroxime may result in the overgrowth of non-susceptible organisms (e.g. Candida, enterococci, Clostridium difficile), which may require interruption of treatment..................
4.5 Interaction with Other Medicaments and other forms of Interaction
In common with other antibiotics, cefuroxime may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.
During intravenous administration admixture with other medications in solution should be avoided.
Cefuroxime has been shown to be compatible with metronidazole, azlocillin and xylitol.
Zinacef interferes with tests for glycosuria depending on copper reduction.
Sodium bicarbonate is not recommended for the dilution of Zinacef.
4.8 Undesirable effects
.......Immune system disorders
Uncommon: Skin rash, urticaria and pruritus.
Rare: Drug fever.
Very rare: Interstitial nephritis, anaphylaxis, cutaneous vasculitis....................
Updated on 28 July 2006 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 6.6 - Special precautions for disposal and other handling
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.8 Undesirable Effects
Adverse drug reactions are very rare (<1/10,000) and are generally mild and transient in nature.
The frequency categories assigned to the adverse reactions below are estimates, as for most reactions suitable data for calculating incidence are not available. In addition the incidence of adverse reactions associated with cefuroxime sodium may vary according to the indication.
Data from clinical trials were used to determine the frequency of very common to rare undesirable effects. The frequencies assigned to all other undesirable effects (i.e., those occurring at <1/1000) were mainly determined using post-marketing data, and refer to a reporting rate rather than a true frequency.
The following convention has been used for the classification of frequency:
very common 1/10,
common 1/100 and <1/10,
uncommon 1/1000 and <1/100,
rare 1/10,000 and <1/1000,
very rare <1/10,000.
Infections and infestations
Rare: Candida overgrowth from prolonged use.
Blood and lymphatic system disorders
Common: Neutropenia, eosinophilia.
Uncommon: Leukopenia, decreased haemoglobin concentration, positive Coomb’s test.
Rare: Thrombocytopenia.
Very rare: Haemolytic anaemia.
Cephalosporins as a class tend to be absorbed onto the surface of red cell membranes and react with antibodies directed against the drug to produce a positive Coomb’s Test (which can interfere with cross matching of blood) and very rarely haemolytic anaemia.
Immune system disorders
Hypersensitivity reactions including
Uncommon: Skin rash, urticaria and pruritus.
Rare: Drug fever.
Very rare: Interstitial nephritis, anaphylaxis.
See also Skin and subcutaneous tissue disorders and Renal and urinary disorders.
Gastrointestinal disorders
Uncommon: Gastrointestinal disturbance.
Very rare: Pseudomembranous colitis.
Hepatobiliary disorders
Common: Transient rise in liver enzymes.
Uncommon: Transient rise in bilirubin.
Transient rises in serum liver enzymes or bilirubin occur, particularly in patients with pre-existing liver disease, but there is no evidence of harm to the liver.
Skin and subcutaneous tissue disorders
Very rare: Erythema multiforme, toxic epidermal necrolysis and Stevens Johnson Syndrome.
See also Immune system disorders.
Renal and urinary disorders
Very rare: Elevations in serum creatinine, elevations in blood urea nitrogen and decreased creatinine clearance ( See Warnings and Precautions).
See also Immune system disorders.
General disorders and administration site conditions
Common Injection site reactions which may include pain and thrombophlebitis
6.6 Instruction for Use/Handling
Intramuscular: Add 1 ml Water for Injections to 250 mg Zinacef. Shake gently to produce an opaque suspension.
Intravenous: Dissolve Zinacef in Water for Injections using at least 2 ml for 250 mg cefuroxime.
Updated on 1 November 2005 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - MA number
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 13 October 2004 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 9 August 2004 SmPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 9 - Date of renewal of authorisation
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 7 July 2003 SmPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Product subject to medical prescription which may not be renewed (A)